找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Decision Making in a World of Comparative Effectiveness Research; A Practical Guide Howard G. Birnbaum,Paul E. Greenberg Book 2017 Springer

[復制鏈接]
樓主: purulent
11#
發(fā)表于 2025-3-23 13:25:26 | 只看該作者
12#
發(fā)表于 2025-3-23 17:06:21 | 只看該作者
Ghassen Hamdi,Mohamed Nazih Omrir market access in the United States. Payers evaluate a drug’s clinical safety and effectiveness profile in relation to existing standards of care. The collected evidence is referred to here as comparative effectiveness research (CER). Augmented with evidence from cost-effectiveness and budget-impac
13#
發(fā)表于 2025-3-23 20:48:39 | 只看該作者
14#
發(fā)表于 2025-3-23 23:40:27 | 只看該作者
15#
發(fā)表于 2025-3-24 04:59:42 | 只看該作者
Database and Expert Systems Applicationsbroad patient population. The recently increased emphasis on comparative effectiveness research (CER) has heightened both the level of evidence and awareness related to the potential for better targeting of treatments. However, a number of practical hurdles to implementation of such targeting by cli
16#
發(fā)表于 2025-3-24 09:33:44 | 只看該作者
17#
發(fā)表于 2025-3-24 12:10:18 | 只看該作者
Lecture Notes in Computer Sciencenswer whether interventions work in real-world settings, whereas explanatory clinical trials are conducted under stricter settings with tighter control to answer whether an intervention can work. While both explanatory and pragmatic trials can have patient-centered elements, pragmatic trials more di
18#
發(fā)表于 2025-3-24 16:19:36 | 只看該作者
Anne V. D. M. Kayem,Christoph Meinelide. CER-based evidence is key to informing the process of health technology assessment (HTA), a policy-oriented form of systematic research that aims to assess the clinical, economic, social, and ethical effect of health technologies. In many countries around the world, the results of HTA are incre
19#
發(fā)表于 2025-3-24 20:43:27 | 只看該作者
Past Indeterminacy in Data Warehouse Designon-oncological drugs. This chapter will begin with providing an introduction to the Canadian Agency for Drugs and Technologies in Health (CADTH) and its role within the Canadian health-care system and will then describe and provide a commentary on the intricacies of the CDR process. The pathway of t
20#
發(fā)表于 2025-3-25 00:07:22 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-25 23:54
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
谷城县| 静宁县| 南川市| 鄂温| 措美县| 东光县| 宝鸡市| 连山| 高邑县| 汾西县| 芮城县| 霍林郭勒市| 峡江县| 韩城市| 邹城市| 江油市| 肇东市| 乌拉特中旗| 绥江县| 宁津县| 虹口区| 洪洞县| 九江市| 河间市| 沛县| 延庆县| 岑巩县| 海盐县| 芮城县| 凤阳县| 石屏县| 长寿区| 乾安县| 莫力| 财经| 吉木萨尔县| 仙游县| 大荔县| 彭阳县| 青州市| 南宁市|